Full-Time

Senior Marketing Operations Specialist

Bracing and Supports

Posted on 9/5/2025

ENOVIS

ENOVIS

1,001-5,000 employees

Global medical technology company; orthopedic solutions

No salary listed

No H1B Sponsorship

Remote in USA

Remote

Candidates must be based in the United States.

Category
Growth & Marketing (1)
Required Skills
Power BI
Business Analytics
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree required
  • 5+ years in a marketing operations or sales operations analyst role within healthcare or med device
  • Strong business acumen with executive presence. Will be communicating with senior executives
  • Expert experience in excel that involves collation of several different data sources
  • Demonstrated proficiency in managing analytically rigorous initiatives and multiple projects
  • Deep expertise in sales automation tools (e.g. CRM systems, Allego)
  • Must have 5+ years of experience working within Power BI and solving complex problems
  • Project management experience
  • Strong understanding of 3rd party data (IQVIA, Symphony, Komodo, Clarivate, etc…)
  • Must be extremely detailed oriented as accuracy is key
  • 5+ years of experience in use of business analytics, key performance indicators, and reporting dashboards
Responsibilities
  • Must deliver accurate, timely, and relevant analytics supporting the business to achieve revenue targets
  • Analyze marketing data to identify trends, performance insights, and areas for improvement
  • Subject matter expert in our 3rd party targeting data to analyze segments, market share, competitive landscape, and further go to market strategies for new product launches
  • Partner with VP of Marketing and their direct team of Directors and Product Managers on KPI development, dashboards and automation of key reports, and process improvements
  • Support the development and execution of the Monthly and QBR dashboards
  • Work collaboratively across multiple stakeholders to ensure alignment and effective campaign execution
  • Collaborate with the Power BI Data Analyst on automating and developing accurate & timely Marketing dashboards
  • Proactively identify and discuss opportunities for data-driven improvements across the Marketing functions
  • Significant involvement on the strategic planning process and data analyses
  • Partners with Senior Sales Operations Analysts on account targeting, segmentation, territory sizing and optimization, quota setting that aligns with the strategic plan
Desired Qualifications
  • Master’s degree in a business-related field would be advantageous
  • Agile and able to multitask, prioritize, and work efficiently under tight deadlines
  • Former sales and/or marketing experience
  • Exceptional presentation skills and PowerPoint creation
  • Strong technical, analytical, and quantitative skills with experience in business analytics, KPIs, and reporting dashboards
  • Highly organized, and process-driven with a proactive, can-do attitude
  • Commitment to the successful achievement of team and organizational goals

Enovis develops medical devices and services to improve patient outcomes and restore mobility. It operates Prevention & Recovery with orthopedic braces, soft goods, vascular therapy, compression garments, and hot/cold therapy, and Reconstructive with joint implants and surgical tools such as Novastep. It differentiates itself through a broad clinically oriented portfolio, a global footprint, and the EGX continuous improvement program, plus the LimaCorporate acquisition expanding its transatlantic reach. Its goal is to provide better patient outcomes and mobility worldwide through sustained growth and operational excellence.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Extremities segment achieves 10% organic growth led by double-digit shoulder gains.
  • ARVIS robot deployment starts with South Africa procedure, adoption expands through 2026.
  • BTIG initiates Buy rating with $41 target on new launches in hips and knees.

What critics are saying

  • $1.18B goodwill impairment from LimaCorporate overpayment erodes R&D capital now.
  • Stryker Mako captures 60% US robotic shoulder procedures, blocks ARVIS adoption by 2027.
  • Zimmer Biomet Persona IQ steals Nebula conversions, slows recon growth by mid-2027.

What makes ENOVIS unique

  • Enovis leverages Enovis Growth Excellence system for continuous operational improvements.
  • Enovis offers ARVIS shoulder robot and Augmented Reverse Glenoid System for extremities.
  • Enovis integrates LimaCorporate acquisition to expand reconstructive implant portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Legal Services

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

32%
Yahoo Finance
Feb 28th, 2026
Enovis reports strong revenue growth and new device uptake despite $1.18B goodwill impairment

Enovis Corporation has reported strong organic revenue growth driven by new product launches, including the Nebula Stem and OrthoDrive Impactor, which have seen rapid market uptake. The medical technology company's devices are gaining traction with surgeons and hospitals. However, Enovis recorded a significant goodwill impairment charge in its fourth quarter and full-year results, affecting its balance sheet. The impairment raises questions about returns from previous acquisitions and future capital allocation strategy. Trading at $25.47, Enovis shares are approximately 44% below the analyst price target of $45.18. The company currently shows a loss of $1.18 billion and trades at a forward price-to-earnings ratio of 25.73 times. Investors are advised to monitor how product adoption and procedure volumes affect future cash flow.

Yahoo Finance
Feb 26th, 2026
Enovis stock jumps 12.6% on strong 2026 earnings forecast despite Q4 revenue miss

Enovis Corporation shares jumped 12.6% in morning trading after the medical technology company reported mixed fourth-quarter results but issued a strong earnings forecast for 2026. Whilst quarterly revenue of approximately $576 million missed expectations, adjusted earnings per share of $0.95 beat analyst estimates. The stock surge was driven by Enovis's 2026 earnings guidance of $3.52 to $3.73 per share, with the midpoint significantly exceeding analyst projections. This positive profit outlook overshadowed the revenue shortfall. Enovis shares have experienced high volatility, with 26 moves exceeding 5% over the past year. The stock is down 6.6% year-to-date and trading 38.1% below its 52-week high of $40 from March 2025.

Yahoo Finance
Feb 26th, 2026
Enovis reports $520.6M Q4 loss despite adjusted earnings of 95 cents per share

Enovis Corporation reported a fourth-quarter loss of $520.6 million, or $9.10 per share. The Wilmington, Delaware-based manufacturing and engineering company posted adjusted earnings of 95 cents per share, excluding asset impairment and non-recurring costs. Revenue for the quarter reached $575.8 million. For the full year, Enovis reported a loss of $1.18 billion, or $20.75 per share, on revenue of $2.25 billion.

Yahoo Finance
Jan 23rd, 2026
BTIG initiates Enovis with $41 target as orthopedic tech firm eyes growth from new product launches

Enovis Corporation has received positive analyst coverage, with BTIG initiating a Buy rating and $41 price target on 6 January. The orthopedic care company is expected to see accelerated growth in 2026 driven by new product launches across extremities, hips and knees. BTIG highlighted the company's consistent mid-to-high single-digit organic revenue growth in its Reconstruction and Prevention & Recovery segments. The higher-growth Reconstruction business is expected to drive margins whilst the mature Prevention & Recovery segment delivers steady cash flow. UBS maintained its Buy rating but lowered its price target to $50 from $57, projecting sales of $2.26 billion in 2025, $2.37 billion in 2026 and $2.52 billion in 2027.

TradingView
Dec 10th, 2025
Enovis secures $700M term loan and $1.1B credit facility, extends maturity to 2030

Enovis Corp has entered Amendment No. 3 to its credit agreement on 8 December, extending the loan maturity date to 8 December 2030. The amended agreement provides a revolving credit facility of up to $1.1 billion and a term loan facility of $700 million. The company used term loan proceeds to repay $335 million from its revolving facility. The amendment restructures Enovis's debt arrangements, providing the medical technology company with extended financing flexibility through the end of the decade.

INACTIVE